NCT04776096 - Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

August 18, 2022

Study Completion Date

August 18, 2022

Conditions

Allergic Conjunctivitis

Interventions

DRUG

Bepotastine Besilate 1.5% PF

Bepotastine besilate 1,5% Preservative free ophthalmic solution

DRUG

Olopatadine Hydrochloride 0.2% BAK

Olopatadine hydrochloride 0.2% with BAK as preservative

Trial Locations (4)

Hospital de Alta Complejidad El Cruce - Nestor Kirchner, CABA

Hospital Santa Lucía, CABA

Instituto Oftalmológico Pedro Lagleyze, CABA

Hospital Churruca - Visca, CABA